Key result
Excision of the expanded (CTG)2600 repeat by gene editing restored the ability of congenital myotonic dystrophy myoblasts to engage in myogenic fusion and normalized early differentiation abnormalities.
Why the study?
Production of toxic transcripts with long trinucleotide tracts impairs myogenic differentiation capacity in congenital myotonic dystrophy, prompting investigation into whether gene-editing repeat excision can normalize early differentiation programs.
Does excision of the expanded (CTG)n repeat restore myogenic differentiation capacity in congenital myotonic dystrophy myoblasts?
Does excision of the expanded (CTG)n repeat restore myogenic differentiation capacity in congenital myotonic dystrophy myoblasts?
Repeat-directed genome editing can reverse molecular and cellular features of congenital myotonic dystrophy in vitro, providing proof-of-concept for future gene therapies.
May inform gene therapy development for cDM; leaves open translation from myoblasts to in vivo or clinical use.
. The production of toxic transcripts with long trinucleotide tracts from these genes results in impairment of the myogenic differentiation capacity as cDM's most prominent morpho-phenotypic hallmark. In the current in vitro study, we compared the early differentiation programs of isogenic cDM myoblasts with and without a (CTG)2600 repeat obtained by gene editing. We found that excision of the repeat restored the ability of cDM myoblasts to engage in myogenic fusion, preventing the ensuing myotubes from remaining immature. Although the cDM-typical epigenetic status of the DM1 locus and the expression of genes therein were not altered upon removal of the repeat, analyses at the transcriptome and proteome level revealed that early abnormalities in the temporal expression of differentiation regulators, myogenic progression markers, and alternative splicing patterns before and immediately after the onset of differentiation became normalized. Our observation that molecular and cellular features of cDM are reversible in vitro and can be corrected by repeat-directed genome editing in muscle progenitors, when already committed and poised for myogenic differentiation, is important information for the future development of gene therapy for different forms of myotonic dystrophy type 1 (DM1).
No takes yet. Share an insight, caveat, or question.
André et al. (2019) studied Congenital myotonic dystrophy (cDM). Excision of the expanded (CTG)2600 repeat by gene editing vs. cDM myoblasts with the (CTG)2600 repeat was evaluated on Myogenic differentiation capacity (myogenic fusion, temporal expression of differentiation regulators, myogenic progression markers, alternative splicing patterns). Excision of the expanded (CTG)2600 repeat by gene editing restored the ability of congenital myotonic dystrophy myoblasts to engage in myogenic fusion and normalized early differentiation abnormalities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: